IRVINE, CA / ACCESSWIRE / March 6, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. ("Stemline" or the "Company") (STML). Investors, who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.
If you purchased shares of Stemline during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
On February 2, 2017, Bloomberg disclosed that a patient in a clinical trial of Stemline's cancer drug SL-401 died from a side effect. This is the third death linked to SL-401 toxicity. When this information was announced to the public, the value of Stemline stock fell significantly, causing investors serious harm.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
If you wish to learn more about this lawsuit at, no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.
Joon M. Khang, Esq.
SOURCE: Khang & Khang LLP